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Key Messages: 
• HPV infection among adolescent girls attending secondary school in Tanzania was 
high (32.5%), and high-risk (HR) oncogenic genotypes were detected in over half 
the girls with HPV infection 
• HPV infection was inversely associated with Lactobacillus species, key 
constituents of optimal vaginal microbiota. 
• The Tanzanian national programme is vaccinating with Gardasil, which protects 
against 2/13 (15%) HR genotypes circulating in our study population, including 
the most prevalent one (HPV-16).   
• Extending the age range of vaccination in this region, where cervical cancer 
screening is extremely limited, may be cost-effective.   
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Abstract 
Objectives:  Cervical cancer is the leading cause of cancer-related mortality among 
women in sub-Saharan Africa (SSA). Data on HPV epidemiology in adolescent girls in SSA 
are essential to inform HPV vaccine policy recommendations for cervical cancer 
prevention.  We assessed the burden of HPV infection, and risk factors for infection, 
among adolescent girls around the time of sexual debut. 
Methods:  Cross-sectional study of secondary school girls aged 17-18 years in Tanzania.  
Consenting participants provided samples for HPV and STI testing.  Vaginal swabs were 
tested for 37 HPV genotypes by Roche Linear Array®.  Logistic regression was used to 
identify factors associated with HPV infection. Y-chromosome was tested as a marker of 
recent condom-less sex. 
Results:  163/385 girls (42.3%) reported previous penetrative sex.  HPV was detected in 
125/385 (32.5%) girls, including 84/163 (51.5%) girls reporting previous sex and 
41/222 (18.5%) reporting no previous sex.  High-risk (HR) genotypes were detected in 
70/125 (56.0%) girls with HPV infection. The most common HR genotype was HPV-16 
(15/385; 3.9%).  The prevalence of other HR HPV vaccine genotypes was between 0.8%-
3.1%.  Among 186 girls who reported no previous sex, were negative for Y-chromosome 
and had no sexually transmitted infections, 32 (17%) had detectable HPV.  Lactobacillus 
species and bacterial vaginosis (BV)-associated bacteria were negatively and positively 
associated, respectively, with HPV.   
Conclusions:  HPV prevalence among adolescent girls around the time of sexual debut 
was high.  However, prevalence of most vaccine genotypes was low, indicating that 
extending the age range of HPV vaccination in this region may be cost-effective. 
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INTRODUCTION 
Cervical cancer is the leading cause of cancer mortality among women in sub-Saharan 
Africa (SSA), and East Africa bears one of the highest burdens, with an age-standardised 
incidence of 40/100,000 and mortality rate of 30/100,000.[1]  Almost all cervical cancers 
can be attributed to persistent infection with one of 13 high-risk (HR) genotypes of human 
papillomavirus (HPV).[2]  In addition to its oncogenic potential, HPV may also be an 
important co-factor in HIV acquisition.[3]   
Infection with up to 7 HR and 2 low risk (LR) HPV genotypes can be prevented with HPV 
vaccination.[4]  However the vaccine offers less protection once an HPV genotype has 
been acquired. Vaccination is recommended before first sex since the predominant 
mechanism of HPV acquisition is thought to be through penetrative sex.[5]  HPV incidence 
increases rapidly after first sex and with changes of sexual partner, although most 
infections are cleared within 12 months.[6,7]  Reviews of global age-specific HPV 
prevalence show the highest prevalence in women aged <25 years.[8]  Most women are 
assumed to be HPV negative before first sex; however, some studies have detected HPV 
in girls and young women who report no previous penetrative sex.[9,10]   
The few published studies on HPV infection in adolescent girls in SSA suggest that HPV 
prevalence may be very high at a young age.  A study in Tanzania found HPV prevalences 
of 73% in sexually active girls aged 14-18 years, and one in Uganda in girls aged 12-24 
found a prevalence of 75%.[11,12]  A recent study in Tanzanian girls aged 15-16 years 
who reported no previous penetrative sex found an HPV prevalence of 8%.[13]  The 
prevalence of non-optimal vaginal microbiota, including bacterial vaginosis (BV), is 
particularly high in SSA.[14]  The vaginal microbiome may modulate susceptibility to HPV 
infection, as well as other sexually transmitted infections (STI) and HIV.[15] 
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There is an important need for data on HPV epidemiology in adolescent girls in SSA in 
order to inform HPV vaccine policy recommendations, to help allocate scarce public-
health resources efficiently and achieve the greatest public health gains, especially as 
vaccine supplies are currently constrained.[16]  Policymakers in SSA may not be able to 
draw conclusions from other settings because of differences in demographic structure, 
sexual behaviour, HPV genotype distribution, and co-factors such as HIV infection.  As part 
of a cross-sectional study of the vaginal microbiota of girls aged 17-18 years in secondary 
schools in Tanzania, over half of whom reported no previous sex, we measured the burden 
of HPV infection and risk factors for infection.   
METHODS 
Study design 
The study design and procedures have been reported previously.[17]  Briefly, this was a 
cross sectional survey in Mwanza, north-western Tanzania.  Girls were enrolled between 
November 2013-June 2014 from government-funded secondary schools; selected schools 
had at least 25 girls in the target age range.  Inclusion criteria were being aged 17-18 
years, resident in Mwanza, and planning to stay in Mwanza for 1 month post-enrolment. 
Exclusion criteria were being outside the age range; being unwilling/unable to provide 
informed assent/consent (or parent unable/unwilling to provide informed consent, if 
aged 17); being temporarily in Mwanza, or planned travel within 1 month post-
enrolment. 
Girls were interviewed about socio-demographics, hygiene practices, and sexual 
behaviours.  Participants provided 5 self-administered vaginal swabs in the presence of a 
nurse who assisted them if needed.  Blood and urine samples were collected. Participants 
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were offered HIV voluntary counselling and testing, with referral for care if positive.  
Laboratory results for treatable STI and free treatment as required were provided to 
participants within 2 weeks. 
Laboratory methods 
Laboratory procedures have been described previously.[17]  HPV genotyping used the 
Linear Array HPV Genotyping assay (Roche Molecular Systems, USA), which detects 37 
genotypes.  DNA was extracted using the AmpliLute Liquid Media Extraction kit (Roche 
Molecular Systems), and amplified using the Linear Array HPV Genotyping Test. 
Generated amplicons were detected using the Linear Array Detection Kit.  PCR reaction in 
this assay is based on a multiplex system, including human β-globin amplification 
primers, as an internal control for specimen quality. Specimens consistently negative for 
β-globin amplification were excluded since it was assumed that vaginal sampling was 
unsuccessful, or the extraction or amplification failed. DNA extraction, amplification and 
typing were performed in different rooms and included negative processing controls.   
Vaginal swabs were tested for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) 
and Mycoplasma genitalium (MG) by in-house real-time PCR.[17]  Concentrations of 
Lactobacillus crispatus, L. gasseri, L. jensenii, L. iners, L. vaginalis, Gardnerella vaginalis, 
Atopobium vaginae were measured using quantitative (q)PCR as previously 
described,[18] with DNA extraction by the QIAmp DNA mini kit. Primers and probes were 
from Eurogentec S.A. (Belgium) and PCRs were run on the QIAGEN Rotorgene.  Gram-
stained vaginal smears were examined for BV using the Nugent score.  Trichomonas 
vaginalis (TV) was diagnosed by culture (InPouch TV, BioMed Diagnostics, USA). Serum 
samples were tested for HSV-2 antibodies by ELISA (Kalon Biological, UK). Syphilis was 
determined by Immutrep Rapid Plasma Reagin (Omega Diagnostics, Scotland) and 
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Treponema pallidum particle agglutination assay (SERODIA, Fujirebio, Japan).  Blood 
samples were tested with Determine HIV1/2 rapid test (Alere, Japan), then Uni-Gold HIV  
(Trinity Biotech, Ireland) if reactive. If both tests were reactive, the result was deemed 
positive. If tests were discordant, the sample was tested with HIV1/2 Stat-Pak (Chembio, 
USA), and deemed positive if reactive. Swabs from girls who reported no previous sex 
were tested for Y-chromosome using an in-house real time PCR, as a marker of recent 
condom-less sex.[19]  Y-chromosome can be detected for up to 15 days, so may provide a 
rough measure of reporting bias. 
Except for Y-chromosome testing, all tests were done at the National Institute for Medical 
Research (NIMR) laboratory, Mwanza.  Quality assurance (QA) and Y-chromosome testing 
were performed by the STI Reference Laboratory at ITM Antwerp. 
Statistical methods 
Questionnaire data were double-entered into OpenClinica (Akaza Research, USA), and 
analysed using STATA V14.0 (StataCorp, USA).      
Participant characteristics, and the number of infections of each HPV genotype, were 
tabulated among girls who reported no previous penetrative sex and those who had 
passed sexual debut (termed ‘sexually active’).  Socioeconomic status was measured using 
a deprivation score, based on household ownership of 3 items:  1=car (least deprived); 
2=television, without car; 3=mobile phone, without car or television; 4=none of the 3 
items (most deprived).  We used logistic regression to estimate odds ratios (OR) and 95% 
confidence intervals (CI) for factors associated with any HPV infection among all girls.  
Potential determinants of HPV infection were examined using a conceptual framework 
with 3 levels: sociodemographic, behavioural, and biological factors.  Age was considered 
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an a priori confounder and included in all models.  First, sociodemographic factors whose 
age-adjusted association with HPV infection was significant at p<0.10 were included in a 
multivariable model; those remaining associated at p<0.10 were retained.  Behavioural 
factors were then added to this model one by one.  Those that were associated with HPV 
at p<0.10, after adjusting for sociodemographic factors, were retained if they remained 
significant at p<0.10.  Associations with biological factors were determined in a similar 
way.  This strategy allowed us to assess the effects of variables at each level of the 
framework, adjusted for more distal variables.  We used a similar approach to examine 
sexual behaviour factors associated with HPV infection among girls who reported being 
sexually active. 
Ethical considerations 
The Institutional Review Board of the Institute of Tropical Medicine in Antwerp (867/13), 
the Ethics Committee of the University Teaching Hospital in Antwerp (13/14/147), the 
Lake Zone Institutional Review Board in Mwanza (MR/53/100/86) and the National 
Ethics Committee of the NIMR Coordinating Committee (NIMR/HQ/R.8a/Vol.IX/1544) 
approved the study protocol.  All participants provided written informed consent/assent; 
written parental consent was required for participants <18 years. 
RESULTS 
Characteristics of study participants 
We identified 26 eligible secondary schools; 24 participated in the study.  1210 girls aged 
17-18 years were registered on the school lists; 802 (66%) were located and their parents 
invited to a meeting about the study.  439 parents (55%) attended the meeting and 421 
(96%) agreed to their daughter’s participation.  401/421 (95%) girls consented/assented 
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and were enrolled (50% of those located; 33% of those on the school lists).  Of these, 385 
(97%) had HPV results and were included in the analysis. 
Overall, 222 (58%) participants reported never having had penetrative sex.  Of those who 
reported previous sex, 61% (99) had passed sexual debut in the past year.  Sexually active 
girls were older than those who reported no previous sex (51% vs. 39% aged 18 years, 
respectively; p=0.02); however, there was no evidence of a difference in other 
sociodemographic characteristics (Table 1).  Nearly all participants (381; 99%) had 
passed menarche, at a median age of 14 years (IQR 14-15).  Among girls who reported no 
previous sex, 20 (9%) reported non-penetrative sexual contact with a male partner (e.g. 
kissing, genital touching).   
The overall prevalence of any STI was 21% among girls who reported previous sex (TV 
9% , CT 5%, NG 2%, MG 4%, HSV2 3%,  HIV 0%), and 7% among girls who reported no 
previous sex  (TV 1%, CT <1%, NG 1%, MG 1%, HSV2 2%, HIV 1%).  BV prevalence among 
girls who reported previous sex was 33%, and 19% among those reporting no previous 
sex. 
Prevalence of HPV genotypes 
387/401 girls provided vaginal swabs for HPV testing (6 were pregnant, 8 refused); β-
globin was detected in 385/387 specimens.  The prevalence of any HPV infection was 
32.5% (125/385);  64/125 girls (51.2%) with HPV infection had >1 genotype. The most 
prevalent HR genotypes were HPV-16 (3.9%), HPV-39 and HPV-52 (both 3.1%), and HPV-
58 (2.9%) (Figure 1). HPV-18 was detected in 3 girls (0.8%). 17 girls (4.4%) were infected 
with HPV-16 and/or HPV-18, the HR genotypes targeted by all HPV vaccines. 53 girls 
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(13.8%) were infected with a genotype targeted by the new 9-valent HPV vaccine, 
Gardasil-9.  
HPV prevalence varied by self-reported sexual behaviour (online supplementary material 
Table S1; Figures S1 and S2). HPV was detected in 84/163 (51.5%) sexually active girls 
and 41/222 (18.5%) girls who reported no penetrative sex.  HR HPV was detected in 47 
(28.8%) sexually active girls, and 23 (10.4%) who reported no penetrative sex.  Among 
those with HR HPV, 31.9% of sexually active girls and 13.0% of those who reported no 
penetrative sex were infected with >1 HR genotype.  The most common HR genotypes 
among sexually active girls were HPV-52 (6.7%), HPV-16 (5.5%), HPV-39 and HPV-68 
(both 4.9%).  Among girls who reported no penetrative sex, the most common HR 
genotypes were HPV-16 and HPV-58 (both 2.7%).   
Among the 222 girls who reported no penetrative sex, 19 (9%) were either positive for Y-
chromosome (N=7) or had laboratory-confirmed STI other than HPV (N=12).  HPV 
prevalence among the 186 girls who reported no sexual contact nor penetrative sex, and 
had no evidence of Y chromosome nor any STI, was 17.2% (N=32). 
Factors associated with HPV infection  
In the unadjusted analysis among all girls, there was some evidence of an association of 
HPV with increasing deprivation score, and strong evidence of an association with sexual 
behaviour (penetrative sex, kissing, engaging in genital touching; Table 2).  There was also 
evidence of an association with vaginal cleansing and menstrual hygiene.  After adjusting 
for age, deprivation score and penetrative sex, there was still strong evidence of an 
association with menstrual hygiene (p=0.004), with participants who used cloths instead 
of commercial pads having the lowest odds of HPV infection, and those who used only 
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underwear having the highest odds of infection.  There was also weak evidence of an 
association with vaginal cleansing (aOR=1.70, 95%CI=0.92-3.16, p=0.09).  After adjusting 
for age, deprivation score, penetrative sex, menstrual hygiene and vaginal cleansing, there 
was evidence of an association with gonorrhoea (aOR=5.70, 95%CI=0.91-35.6), MG 
(aOR=6.01, 95%CI=1.08-33.6), HIV (aOR=10.4, 95%CI=0.90-121.5) and BV (aOR=1.93, 
95%CI=1.13-3.29). 
Among sexually active girls, after adjusting for age and deprivation score, there was 
evidence of an association of HPV with having >1 lifetime partner (aOR=2.63, 
95%CI=1.22-5.69), an older first partner, and a first partner who had concurrent partners 
(online supplementary material Table S2).  There was also evidence of an association with 
time since sexual debut, with HPV infection highest among those whose sexual debut was 
1-2 years ago (aOR=2.29, 95%CI=1.01-5.21, relative to those with sexual debut <1 year 
ago). 
Association with vaginal microbiota  
Among all girls, after adjusting for age, deprivation score and penetrative sex, HPV 
infection was positively associated with A. vaginae (aOR=2.19, 95%CI=1.32-3.64; 
p=0.002) and G. vaginalis (aOR=1.79, 95%CI=1.05-3.04) (Table 3).  In contrast, HPV 
infection had an inverse association with several Lactobacillus species, including L. 
crispatus (aOR=0.48, 95%CI=0.29-0.80; p=0.005) and L. jensenii (aOR=0.44, 95%CI=0.27-
0.73; p=0.001), and, to a lesser extent, L vaginalis.  The same trends were seen for the 
association with high levels (>1 million cells/mL) of each bacterial species. 
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DISCUSSION 
We found a high prevalence of HPV infection among adolescent Tanzanian girls around 
the time of reported sexual debut.  Over half of sexually active participants and one-fifth 
of those who reported no penetrative sex had HPV infection, and 56% of those infected 
had an HR genotype.  Multiple HPV genotype infections were also very common, with 51% 
of HPV-infected girls having >1 genotype.  These findings are consistent with previous 
studies of HPV in sexually active adolescents in the USA and in Africa.[11,12,20]  
HPV-16 was the most prevalent HR genotype (3.9%).  The prevalence of HPV-18 was <1% 
and of other vaccine genotypes was <3%, except for HPV-52 (targeted by Gardasil-9), 
which was 3.1%.  Similarly, a study in Mozambique found HPV-52, 58 and 16 were the 
most common HR genotypes in young women.[21] Also, a large meta-analysis of HPV 
prevalence worldwide found HPV-16 to be the most common genotype among women in 
SSA, followed by HPV-52.[8]    
The Director General of the World Health Organization recently announced a goal to 
eliminate cervical cancer.[22] Currently vaccination strategies target girls in an age range 
considered to be pre-sexual debut, typically 9-14 years. The optimum upper age limit for 
vaccination will depend on different factors including HPV vaccine genotype prevalence, 
age of sexual debut, cost per dose of vaccine, availability of cervical cancer screening, and 
HPV transmission dynamics. Screening for cervical cancer is extremely limited in 
Tanzania.  Previous studies of HPV epidemiology in Tanzania have shown one of the 
highest reported HPV incidences, and a high prevalence of vaccine-related genotypes 
among young women aged 20-25 years, so the cost-effectiveness of vaccinating girls up 
to 17 years is likely to be high.[11]  Over half the girls in our study reported no previous 
penetrative sex, and most were not yet infected with vaccine-related genotypes.  These 
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findings suggest that a catch-up strategy that goes beyond the multiyear cohort approach 
of vaccinating 9-14 year olds,[23] by offering vaccination to girls aged 15-17 years, could 
help reduce HPV acquisition at a critical time after sexual debut.  Furthermore, this would 
contribute towards the goal of cervical cancer elimination by decreasing the proportion 
of females in the population who would otherwise acquire persistent HPV infection, a 
necessary prerequisite for cervical cancer.  
The Tanzanian national programme is currently vaccinating with Gardasil, which covers 
2/13 (15%) circulating HR genotypes in our study population, but only one of the more 
common ones (HPV-16).  In contrast, Gardasil-9 would cover 7/13 (54%) circulating HR 
genotypes, including the three most common ones. Although Gardasil and Cervarix offer 
some cross-protection for other genotypes (Gardasil against HPV-31, and Cervarix against 
HPV-31, 33, and 45), these cross-protected genotypes were less common in our 
population.   Therefore, Gardasil-9 may offer the best coverage given the distribution of 
HR genotypes in our setting. 
HPV transmission appears extremely efficient in the early years of sexual activity in our 
setting, with >60% of girls whose sexual debut was 1-2 years ago being infected with HPV.  
HPV prevalence among girls who report no  penetrative sex was also high (18.5%), and 
substantially higher than in studies in industrialised countries among women who 
reported no previous sex.   A cross-sectional  study in Sweden in women aged 10-25 years 
who reported no previous sex found a prevalence of 1.5%.[10]  A longitudinal study in 
USA found HPV in only 1.7% of samples from women aged 18-20 who never had sex.[9]  
Our prevalence is also higher than in a longitudinal study in Tanzanian girls aged 15-16 
years who reported no penetrative sex over 18 months, which found HPV in only 11.6% 
of samples.[24]  Lack of disclosure is likely to be part of the explanation for the high HPV 
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prevalence in girls in our study who denied previous sexual activity.  This is supported by 
our finding that 9% of girls who reported no previous sex were positive for Y-
chromosome and/or an STI (excluding HPV).  In Tanzania, girls who are still in school may 
be particularly reluctant to disclose sexual activity, since potential consequences include 
expulsion, physical punishment or social exclusion.[25]   
Alternative explanations for HPV infection in girls who report no previous sex include 
mother-to-child transmission, non-penetrative sexual contact, or transmission via 
fomites.[26,27]   A recent study in Mwanza showed a high prevalence of HPV DNA in oral 
washes and fingertip samples from adolescent girls, and on surfaces in their 
bathrooms.[28] Nevertheless, even with potential reporting errors, our findings of a very 
high HPV prevalence in girls who report no penetrative sex is important.   
After adjusting for potential confounders, we found a strong inverse association between 
HPV and D-lactic-acid and H2O2-producing Lactobacillus species, including L. crispatus 
and L. jensenii, key constituents of optimal vaginal microbiota.  Furthermore, there was a 
strong positive association between HPV infection and anaerobic bacterial species G. 
vaginalis and A. vaginae.   These species are characteristic of BV, which has been 
associated with increased susceptibility to STI and HIV.[29]  A recent meta-analysis found 
that disturbance in the vaginal microbiota away from a Lactobacillus-dominated 
environment was associated with increased risk of HPV acquisition and persistence, and 
related cervical disease.[30] 
Strengths of our study include detailed interviews given by trained nurses experienced in 
adolescent sexual behaviour research.  Collection of vaginal swabs, although self-
administered, was observed by nurses; all but 2 specimens contained β-globin, indicating 
successful sampling and specimen processing.  The Roche Linear Array used for HPV 
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genotyping has a high sensitivity and specificity; all laboratory assays were conducted 
according to SOPs with external QA at an internationally-recognised reference laboratory. 
Limitations include the cross-sectional design, which makes it difficult to assess causality 
or to measure past HPV infection, since individual genotype-specific infections may be 
rapidly cleared.[7]   Face-to-face interviews may have increased social desirability bias in 
responses; the inclusion of parents and recruitment from schools may have compounded 
this issue.  We enrolled girls who were still in school; many girls in this age range in 
Tanzania are no longer in school.  Unpublished demographic and health survey (DHS) 
data from the Mwanza region in 2017 showed 41% of girls aged 17-18 years were still in 
school.  Furthermore, only 33% of 1210 girls on the school lists were enrolled, mostly 
because they were not found at the school or their parents could not be located, which 
suggests possible selection bias. National DHS data show that young women with 
secondary education have an older age at first sex, and later age at first birth.[31]  
Therefore, we may have underestimated HPV prevalence among all women in this age 
group.  However, our findings of the distribution of HPV genotypes, and factors associated 
with HPV, are consistent with other studies in SSA, and may be more broadly 
generalisable. 
In conclusion, we found a high prevalence of HPV infection, and HR genotypes, among 
adolescent girls in the early years after becoming sexually active, and among girls who 
reported no penetrative sex.  HPV vaccination in Tanzania is currently offered to 14 year 
old girls through a national vaccination programme.  The prevalence of most vaccine-
related genotypes was low, indicating that extending the age range of HPV vaccination 
through a catch-up campaign in this region, with one of the highest rates of cervical cancer 
worldwide and limited facilities for screening, may be cost-effective. 
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Table 1.  Characteristics at enrolment of 385 adolescent girls attending secondary 
school in Mwanza, Tanzania 
 Report no 
previous 
penetrative sex 
(N=222)  
n (column%) 
Report previous 
penetrative sex 
(N=163) 
n (column%) 
All girls (N=385) 
n (column%) 
Sociodemographic     
Age    
17 years 135 (61%) 80 (49%) 215 (56%) 
18 years 87 (39%) 83 (51%) 170 (44%) 
Tribe    
Sukuma 99 (45%) 70 (43%) 169 (44%) 
Non-Sukuma 123 (55%) 93 (57%) 216 (56%) 
Religion    
Catholic 97 (44%) 87 (53%) 184 (48%) 
Other Christian 88 (40%) 54 (33%) 142 (37%) 
Muslim 32 (14%) 20 (12%) 52 (14%) 
Other 5 (2%) 2 (1%) 7 (2%) 
Secondary school form    
Form 1 2 (1%) 1 (1%) 3 (1%) 
Form 2 47 (21%) 21 (13%) 68 (18%) 
Form 3 127 (57%) 99 (61%) 226 (59%) 
Form 4 46 (21%) 42 (26%) 88 (23%) 
Who lives with    
Mother in household 146 (66%) 98 (60%) 244 (63%) 
Father but not mother 12 (5%) 12 (7%) 24 (6%) 
Neither mother or father 64 (29%) 53 (33%) 117 (30%) 
Deprivation score    
1 (least deprived) 16 (7%) 8 (5%) 24 (6%) 
2 88 (40%) 76 (47%) 164 (43%) 
3 110 (50%) 73 (45%) 183 (48%) 
4 (most deprived) 8 (4%) 6 (4%) 14 (4%) 
Behavioural    
Ever drink alcohol?    
Yes 6 (3%) 5 (3%) 11 (3%) 
Ever kissed with tongues    
Yes 19 (9%) 76 (47%) 95 (25%) 
Ever engaged in genital 
touching1  
   
Yes 3 (1%) 40 (25%) 43 (11%) 
Ever had oral sex2    
Yes 1 (<1%) 9 (6%) 10 (3%) 
Ever had anal sex    
Yes 0 2 (1%) 2 (1%) 
Passed menarche    
Yes 218 (98%) 163 (100%) 381 (99%) 
 page 22 
 
Ever cleanse inside vagina    
Yes 16 (7%) 42 (26%) 58 (15%) 
1Sexual touching with a man/boy where girl touched his penis with her hand, he touched her vagina with 
his hand, or he rubbed his penis on her legs/buttocks/genitals but did not have vaginal sex. 2Ever had 
man/boy put his penis in girl’s mouth, or he licked/sucked the girl’s genitals.   
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Table 2.  Factors associated with any HPV infection among 385 adolescent girls 
attending secondary school in Mwanza, Tanzania  
  N with HPV / total 
N (%) 
Crude OR  
(95% CI) 
 
Sociodemographic     
Age  P=0.40  
17 years 66 / 215 (30.7%) 1  
18 years 59 / 170 (34.7%) 1.20  (0.78–1.84 )  
Tribe  P=0.85  
Sukuma 54 / 169 (32.0%) 1  
Non-Sukuma 71 / 216 (32.9%) 1.04  (0.68–1.60 )  
Religion  P=0.60  
Catholic 59 / 184 (32.1%) 1  
Other Christian 51 / 142 (35.9%) 1.19  (0.75–1.88 )  
Muslim 15 / 52 (28.8%) 0.86  (0.44–1.69 )  
Other 0 / 7 (0.0 %) –  
Who lives with  P=0.86  
Mother in household 79 / 244 (32.4%) 1  
Father but not mother 9 / 24 (37.5%) 1.25  (0.53–2.99 )  
Neither mother or 
father 
37 / 117 (31.6%) 0.97  (0.60–1.55 )  
Deprivation score    
1 (least deprived) 6 / 24 (25.0%)   
2 51 / 164 (31.1%) P=0.09  
3 59 / 183 (32.2%) 1.32  (0.95–1.82 )  
4 (most deprived) 9 / 14 (64.3%)   
Behaviour 
  
Adjusted OR  
(95% CI)1 
Ever drink alcohol?  P=0.28 P=0.24 
No 123 / 374 (32.9%) 1 1 
Yes 2 / 11 (18.2%) 0.45  (0.10–2.13 ) 0.41  (0.08 -2.05 ) 
Ever kissed with tongues  P=0.006 P=0.82 
No 83 / 290 (28.6%) 1 1 
Yes 42 / 95 (44.2%) 1.98  (1.23–3.19 ) 0.94  (0.54 -1.63 ) 
Ever engaged in genital 
touching2 
 P=0.003 P=0.64 
No 102 / 342 (29.8%) 1 1 
Yes 23 / 43 (53.5%) 2.71  (1.42–5.14 ) 1.19  (0.59 -2.40 ) 
Ever had oral sex3  P=0.07 P=0.55 
No 119 / 375 (31.7%) 1 1 
Yes 6 / 10 (60.0%) 3.23  (0.89–11.65) 1.51  (0.39 -5.87 ) 
Ever had vaginal sex  P<0.001 P<0.001 
No 41 / 222 (18.5%) 1 1 
Yes 84 / 163 (51.5%) 4.69  (2.97–7.42 ) 4.81  (3.02 -7.66 ) 
Menstrual hygiene4  P=0.002 P=0.004 
Pads only (+/- pants) 68 / 202 (33.7%) 1 1 
Cloths only  (+/- 12 / 71 (16.9%) 0.40  (0.20–0.80 ) 0.45  (0.22 -0.94 ) 
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pants) 
Pants only 15 / 29 (51.7%) 2.11  (0.96–4.63 ) 2.75  (1.17 -6.46 ) 
Cloth & pads (+/- 
pants) 
30 / 79 (38.0%) 1.21  (0.70–2.07 ) 1.16  (0.65 -2.08 ) 
Ever cleanse inside vagina  P=0.001 P=0.09 
No 95 / 327 (29.1%) 1 1 
Yes 30 / 58 (51.7%) 2.62  (1.48–4.62 ) 1.70  (0.92 -3.16 ) 
Biological     
HSV-2  P=0.45 P=0.48 
Negative 121 / 376 (32.2%) 1 1 
Positive 4 / 9 (44.4%) 1.69  (0.44–6.39 ) 1.70  (0.40 -7.29 ) 
Chlamydia trachomatis  P=0.15 P=0.76 
Negative 120 / 376 (31.9%) 1 1 
Positive 5 / 9 (55.6%) 2.67  (0.70–10.11) 1.25  (0.31 -5.02 ) 
Neisseria gonorrhoeae  P=0.03 P=0.05 
Negative 120 / 378 (31.7%) 1 1 
Positive 5 / 7 (71.4%) 5.37  (1.03–28.10) 5.70  (0.91 -35.56) 
Trichomonas vaginalis  P=0.02 P=0.79 
Negative 115 / 368 (31.3%) 1 1 
Positive 10 / 17 (58.8%) 3.14  (1.17–8.46 ) 1.16  (0.39 -3.45 ) 
Active syphilis 
(RPR+/TPPA+) 
   
Negative 125 / 385 (32.9%) – – 
Positive 0 (–) – – 
HIV  P=0.24 P=0.06 
Negative 123 / 382 (32.2%) 1 1 
Positive 2 / 3 (66.7%) 4.21  (0.38 -46.89)  10.44  (0.90 -121.5)  
Mycoplasma genitalium  P=0.005 P=0.02 
Negative 118 / 376 (31.4%) 1 1 
Positive 7 / 9 (77.8%) 7.65  (1.57–37.39) 6.01  (1.08 -33.56) 
Bacterial vaginosis5  P=0.002 P=0.05 
Normal 71 / 261 (27.2%) 1 1 
Intermediate 9 / 28 (32.1%) 1.27  (0.55–2.93 ) 0.94  (0.36 -2.44 ) 
BV 45 / 95 (47.4%) 2.41  (1.48–3.92 ) 1.93  (1.13 -3.29 ) 
1Behavioural factors adjusted for age (a priori), deprivation score, and vaginal sex.  Biological factors 
adjusted for age, deprivation score, vaginal sex, menstrual hygiene and vaginal cleansing. 2Sexual touching 
with a man/boy where girl touched his penis with her hand, he touched her vagina with his hand, or he 
rubbed his penis on her legs/buttocks/genitals but did not have vaginal sex. 3Ever had man/boy put his 
penis in girl’s mouth, or he licked/sucked the girl’s genitals. 4Sanitary products used for menstrual hygiene; 
most girls who reported using pads or cloths also reported wearing pants (underwear).  Restricted to girls 
who have passed menarche (N=381).  5Missing data for 1 girl. 
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Table 3.  Association of bacterial species with any HPV infection among 385 
adolescent girls attending secondary school in Mwanza, Tanzania  
  N with HPV / total 
N (%) 
Crude OR  
(95% CI) 
Adjusted OR  
(95% CI)1 
Adjusted OR  
(95% CI)2 
Presence/absence     
A. vaginae 3  P<0.001 P<0.001 P=0.002 
Absent 49 / 220 (22.3%) 1 1 1 
Present 63 / 139 (45.3%) 2.89  (1.82-4.59) 2.30  (1.40-3.76) 2.19  (1.32-3.64) 
G. vaginalis 4  P<0.001 P=0.02 P=0.03 
Absent 31 / 145 (21.4%) 1 1 1 
Present 87 / 209 (41.6%) 2.62  (1.62-4.25) 1.87  (1.12-3.14) 1.79  (1.05-3.04) 
L. vaginalis 5  P<0.001 P=0.03 P=0.04 
Absent 59 / 131 (45.0%) 1 1 1 
Present 64 / 242 (26.4%) 0.44  (0.28-0.69) 0.58  (0.36-0.93) 0.60  (0.37-0.98) 
L. crispatus 6  P<0.001 P=0.005 P=0.005 
Absent 55 / 120 (45.8%) 1 1 1 
Present 60 / 238 (25.2%) 0.40  (0.25-0.63) 0.49  (0.30-0.81) 0.48  (0.29-0.80) 
L. gasseri 7  P=0.91 P=0.86 P=0.76 
Absent 98 / 300 (32.7%) 1 1 1 
Present 24 / 75 (32.0%) 0.97  (0.56-1.67) 1.06  (0.59-1.89) 1.10  (0.61-1.99) 
L. iners 8  P=0.08 P=0.20 P=0.37 
Absent 16 / 68 (23.5%) 1 1 1 
Present 106 / 311 (34.1%) 1.68  (0.92-3.08) 1.51  (0.79-2.89) 1.35  (0.69-2.63) 
L. jensenii 5  P<0.001 P<0.001 P=0.001 
Absent 83 / 198 (41.9%) 1 1 1 
Present 37 / 175 (21.1%) 0.37  (0.23-0.59) 0.44  (0.27-0.71) 0.44  (0.27-0.73) 
>1,000,000/mL     
A. vaginae 3  P<0.001 P<0.001 P=0.001 
No 55 / 239 (23.0%) 1 1 1 
Yes 57 / 120 (47.5%) 3.03  (1.90-4.83) 2.37  (1.44-3.92) 2.33  (1.39-3.91) 
G. vaginalis 4  P<0.001 P=0.02 P=0.02 
No 47 / 195 (24.1%) 1 1 1 
Yes 71 / 159 (44.7%) 2.54  (1.61-4.00) 1.83  (1.12-2.98) 1.83  (1.10-3.03) 
L. vaginalis 5  P=0.57 P=0.75 P=0.68 
No 91 / 269 (33.8%) 1 1 1 
Yes 32 / 104 (30.8%) 0.87  (0.53-1.41) 0.92  (0.54-1.55) 0.89  (0.52-1.53) 
L. crispatus 6  P<0.001 P=0.009 P=0.01 
No 59 / 132 (44.7%) 1 1 1 
Yes 56 / 226 (24.8%) 0.41  (0.26-0.64) 0.52  (0.32-0.85) 0.52  (0.32-0.87) 
L. gasseri 7  P=0.57 P=0.41 P=0.34 
No 106 / 331 (32.0%) 1 1 1 
Yes 16 / 44 (36.4%) 1.21  (0.63-2.34) 1.35  (0.67-2.73) 1.42  (0.69-2.91) 
L. iners 8  P=0.05 P=0.24 P=0.52 
No 20 / 85 (23.5%) 1 1 1 
Yes 102 / 294 (34.7%) 1.73  (0.99-3.01) 1.43  (0.79-2.59) 1.22  (0.66-2.25) 
L. jensenii 5  P<0.001 P<0.001 P<0.001 
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No 94 / 238 (39.5%) 1 1 1 
Yes 26 / 135 (19.3%) 0.37  (0.22-0.60) 0.40  (0.24-0.68) 0.38  (0.22-0.65) 
1Adjusted for age (a priori), deprivation score, and vaginal sex.  2Adjusted for age (a priori), deprivation 
score, vaginal sex, menstrual hygiene and vaginal cleansing.   3Missing data for 26 girls.  4Missing data for 
31 girls. 5Missing data for 12 girls.  6Missing data for 27 girls.  7Missing data for 10 girls.  8Missing data for 6 
girls. 
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Figure 1.  HPV genotype-specific prevalence1 among 385 girls attending secondary 
school in Mwanza, Tanzania  
 
 
 
 
 
 
 
 
 
 
 
 
 
1Vertical lines indicate 95% confidence intervals and numbers are raw frequencies. 
 
